Terrific clinical trial data followed by a $9.7 billion buyout offer gave investors lots to be thankful for.
News & Analysis: The Medicines Company
Understanding why can help you identify the next takeout target.
The stock market got off to a solid start in the holiday-shortened week.
Novartis added another key piece to the puzzle over the weekend.
A buyout rumor has investors hopeful.
Clinical data for cholesterol-lowering drug inclisiran looks good.
MDCO earnings call for the period ending September 30, 2019.
The company's flagship cholesterol treatment shows major potential.
The Medicines Company Is Up 161% Year to Date, but Here's a Better Way to Play the Drugmaker's Success
Investors should go to the source.
Amgen is acquiring Otezla, and The Medicines Company unveils stellar data for its cholesterol treatment.